Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. “This is great news for residents, as increased awareness results in increased ...

Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,” the study author said.

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Odds are you’ve heard of GLP-1 drugs like Ozempic for managing type 2 diabetes and shedding pounds. But have you ever wondered what Ozempic does to your brain? Recent research suggests it might ...

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests. Researchers found these medications show promise in ...

A new study adds to mounting evidence showing that drugs like Ozempic don’t just treat diabetes — they can also prevent it. The new paper, published Wednesday in The New England Journal of ...